Thanh C. Cheng MD
Emergency Medicine Physician and Principal Investigator in Stem Cell Clinical Trials
Join to View Full Profile
2752 Sunrise BlvdPearland, TX 77584
Phone+1 713-766-1096
Dr. Cheng is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Thanh Cheng is an emergency medicine physician in Pearland, TX and is affiliated with AetherHealth Silverlake ER. He received his medical degree from Vanderbilt University School of Medicine and has been in practice for over 27 years in emergency medicine. He is also a principal investigator in FDA-approved mesenchymal stem-cell clinical trials for various diseases at Hope Biosciences.
Education & Training
West Virginia UniversityResidency, Emergency Medicine, 1995 - 1998
Vanderbilt University School of MedicineClass of 1995
Certifications & Licensure
TX State Medical License 1998 - 2027
FL State Medical License 2002 - 2005
CA State Medical License 2001 - 2003
WV State Medical License 1998 - 2000
American Board of Emergency Medicine Emergency Medicine
Clinical Trials
- A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs Against COVID-19. Start of enrollment: 2020 May 14
- A Clinical Trial to Determine the Safety and Efficacy of HB-adMSCs to Provide Protection Against COVID-19 Start of enrollment: 2020 Apr 20
- Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome Start of enrollment: 2022 Feb 02
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsSafety and efficacy of adipose-derived mesenchymal stem cell therapy in elderly Parkinson's disease patients: an intermediate-size expanded access program.Ridhima Vij, Hosu Kim, Hyeonggeun Park, Thanh Cheng, Djamchid Lotfi
Cytotherapy. 2025-02-01 - 5 citationsAdipose-derived, autologous mesenchymal stem cell therapy for patients with post-COVID-19 syndrome: an intermediate-size expanded access program.Ridhima Vij, Hosu Kim, Hyeonggeun Park, Thanh Cheng, Djamchid Lotfi
Stem Cell Research & Therapy. 2023-10-05 - 2 citationsLong-term, repeated doses of intravenous autologous mesenchymal stem cells for a patient with Parkinson's disease: a case report.Ridhima Vij, Alan Prossin, Mallika Tripathy, Hosu Kim, Hyeonggeun Park
Frontiers in Neurology. 2023-01-01
External Links
- Linked inhttp://www.linkedin.com/in/thanh-c-61400619
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
